(PATH) Uipath - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US90364P1057
Stock: Automation, Robot, AI, Workflow, Mining
Total Rating 24
Risk 47
Buy Signal -0.62
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.0% |
| Relative Tail Risk | -10.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -33.39 |
| Character TTM | |
|---|---|
| Beta | 1.379 |
| Beta Downside | 0.934 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.58% |
| CAGR/Max DD | -0.08 |
Description: PATH Uipath January 09, 2026
UiPath Inc. (NYSE: PATH) offers a cloud-native, end-to-end automation platform that combines low-code RPA, AI/ML/NLP, and API integration into a single workflow engine. The suite includes “Automation Cloud” for rapid deployment without on-premise infrastructure, a process-mining module that maps digital footprints, and analytics that track and forecast automation performance. Its primary markets span financial services, healthcare, manufacturing, retail, and the public sector, with a geographic focus on the United States, Romania, the United Kingdom, and the Netherlands.
Key recent metrics (FY 2023): revenue $1.86 bn (+33 % YoY), subscription ARR of $2.3 bn (up 38 % YoY), and a gross margin of ~78 %. The RPA market is projected to grow at a CAGR of ~30 % through 2028, driven by enterprise pressure to cut operating costs and the broader AI-automation convergence. A material risk factor is the concentration of revenue in large-enterprise contracts, which can cause earnings volatility if renewal rates dip.
For a deeper, data-driven valuation perspective, you may find the analytics on ValueRay useful for benchmarking UiPath against peers and assessing scenario-based upside potential.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 229.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.84 > 1.0 |
| NWC/Revenue: 78.43% < 20% (prev 104.9%; Δ -26.51% < -1%) |
| CFO/TA 0.12 > 3% & CFO 334.9m > Net Income 229.7m |
| Net Debt (-671.6m) to EBITDA (25.9m): -25.89 < 3 |
| Current Ratio: 2.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (544.7m) vs 12m ago -3.24% < -2% |
| Gross Margin: 83.16% > 18% (prev 0.83%; Δ 8233 % > 0.5%) |
| Asset Turnover: 55.87% > 50% (prev 52.99%; Δ 2.88% > 0%) |
| Interest Coverage Ratio: -0.57 > 6 (EBITDA TTM 25.9m / Interest Expense TTM -40.1m) |
Altman Z'' -1.15
| A: 0.42 (Total Current Assets 2.01b - Total Current Liabilities 788.7m) / Total Assets 2.90b |
| B: -0.63 (Retained Earnings -1.81b / Total Assets 2.90b) |
| C: 0.01 (EBIT TTM 22.7m / Avg Total Assets 2.78b) |
| D: -1.83 (Book Value of Equity -1.78b / Total Liabilities 971.4m) |
| Altman-Z'' Score: -1.15 = CCC |
Beneish M -2.50
| DSRI: 1.01 (Receivables 496.1m/448.2m, Revenue 1.55b/1.41b) |
| GMI: 1.00 (GM 83.16% / 83.20%) |
| AQI: 1.83 (AQ_t 0.27 / AQ_t-1 0.15) |
| SGI: 1.10 (Revenue 1.55b / 1.41b) |
| TATA: -0.04 (NI 229.7m - CFO 334.9m) / TA 2.90b) |
| Beneish M-Score: -2.50 (Cap -4..+1) = BBB |
What is the price of PATH shares?
As of February 07, 2026, the stock is trading at USD 12.89 with a total of 34,254,314 shares traded.
Over the past week, the price has changed by +2.38%, over one month by -25.62%, over three months by -8.84% and over the past year by -9.80%.
Over the past week, the price has changed by +2.38%, over one month by -25.62%, over three months by -8.84% and over the past year by -9.80%.
Is PATH a buy, sell or hold?
Uipath has received a consensus analysts rating of 3.17.
Therefor, it is recommend to hold PATH.
- StrongBuy: 3
- Buy: 1
- Hold: 18
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the PATH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.4 | 27.2% |
| Analysts Target Price | 16.4 | 27.2% |
| ValueRay Target Price | 12.4 | -3.7% |
PATH Fundamental Data Overview February 04, 2026
P/E Trailing = 29.8571
P/E Forward = 17.1233
P/S = 4.3176
P/B = 3.4981
P/EG = 0.4894
Revenue TTM = 1.55b USD
EBIT TTM = 22.7m USD
EBITDA TTM = 25.9m USD
Long Term Debt = 82.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.59m USD (from shortTermDebt, last fiscal year)
Debt = 72.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -671.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.38b USD (6.71b + Debt 72.0m - CCE 1.40b)
Interest Coverage Ratio = -0.57 (Ebit TTM 22.7m / Interest Expense TTM -40.1m)
EV/FCF = 17.27x (Enterprise Value 5.38b / FCF TTM 311.6m)
FCF Yield = 5.79% (FCF TTM 311.6m / Enterprise Value 5.38b)
FCF Margin = 20.06% (FCF TTM 311.6m / Revenue TTM 1.55b)
Net Margin = 14.79% (Net Income TTM 229.7m / Revenue TTM 1.55b)
Gross Margin = 83.16% ((Revenue TTM 1.55b - Cost of Revenue TTM 261.6m) / Revenue TTM)
Gross Margin QoQ = 83.26% (prev 82.20%)
Tobins Q-Ratio = 1.86 (Enterprise Value 5.38b / Total Assets 2.90b)
Interest Expense / Debt = 25.19% (Interest Expense 18.1m / Debt 72.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 18.0m (EBIT 22.7m * (1 - 21.00%))
Current Ratio = 2.54 (Total Current Assets 2.01b / Total Current Liabilities 788.7m)
Debt / Equity = 0.04 (Debt 72.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = -25.89 (Net Debt -671.6m / EBITDA 25.9m)
Debt / FCF = -2.16 (Net Debt -671.6m / FCF TTM 311.6m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.26% (Net Income 229.7m / Total Assets 2.90b)
RoE = 12.88% (Net Income TTM 229.7m / Total Stockholder Equity 1.78b)
RoCE = 1.22% (EBIT 22.7m / Capital Employed (Equity 1.78b + L.T.Debt 82.0m))
RoIC = 1.01% (NOPAT 18.0m / Invested Capital 1.78b)
WACC = 11.09% (E(6.71b)/V(6.78b) * Re(11.0%) + D(72.0m)/V(6.78b) * Rd(25.19%) * (1-Tc(0.21)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.99%
[DCF Debug] Terminal Value 66.96% ; FCFF base≈310.4m ; Y1≈300.3m ; Y5≈297.4m
Fair Price DCF = 8.62 (EV 3.30b - Net Debt -671.6m = Equity 3.97b / Shares 460.4m; r=11.09% [WACC]; 5y FCF grow -4.47% → 2.90% )
EPS Correlation: 37.81 | EPS CAGR: 42.03% | SUE: -4.0 | # QB: 0
Revenue Correlation: 84.15 | Revenue CAGR: 9.78% | SUE: 2.05 | # QB: 3
EPS next Quarter (2026-04-30): EPS=0.15 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=18
EPS next Year (2027-01-31): EPS=0.76 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+13.2% | Growth Revenue=+9.2%
P/E Forward = 17.1233
P/S = 4.3176
P/B = 3.4981
P/EG = 0.4894
Revenue TTM = 1.55b USD
EBIT TTM = 22.7m USD
EBITDA TTM = 25.9m USD
Long Term Debt = 82.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.59m USD (from shortTermDebt, last fiscal year)
Debt = 72.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -671.6m USD (from netDebt column, last quarter)
Enterprise Value = 5.38b USD (6.71b + Debt 72.0m - CCE 1.40b)
Interest Coverage Ratio = -0.57 (Ebit TTM 22.7m / Interest Expense TTM -40.1m)
EV/FCF = 17.27x (Enterprise Value 5.38b / FCF TTM 311.6m)
FCF Yield = 5.79% (FCF TTM 311.6m / Enterprise Value 5.38b)
FCF Margin = 20.06% (FCF TTM 311.6m / Revenue TTM 1.55b)
Net Margin = 14.79% (Net Income TTM 229.7m / Revenue TTM 1.55b)
Gross Margin = 83.16% ((Revenue TTM 1.55b - Cost of Revenue TTM 261.6m) / Revenue TTM)
Gross Margin QoQ = 83.26% (prev 82.20%)
Tobins Q-Ratio = 1.86 (Enterprise Value 5.38b / Total Assets 2.90b)
Interest Expense / Debt = 25.19% (Interest Expense 18.1m / Debt 72.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 18.0m (EBIT 22.7m * (1 - 21.00%))
Current Ratio = 2.54 (Total Current Assets 2.01b / Total Current Liabilities 788.7m)
Debt / Equity = 0.04 (Debt 72.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = -25.89 (Net Debt -671.6m / EBITDA 25.9m)
Debt / FCF = -2.16 (Net Debt -671.6m / FCF TTM 311.6m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.26% (Net Income 229.7m / Total Assets 2.90b)
RoE = 12.88% (Net Income TTM 229.7m / Total Stockholder Equity 1.78b)
RoCE = 1.22% (EBIT 22.7m / Capital Employed (Equity 1.78b + L.T.Debt 82.0m))
RoIC = 1.01% (NOPAT 18.0m / Invested Capital 1.78b)
WACC = 11.09% (E(6.71b)/V(6.78b) * Re(11.0%) + D(72.0m)/V(6.78b) * Rd(25.19%) * (1-Tc(0.21)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.99%
[DCF Debug] Terminal Value 66.96% ; FCFF base≈310.4m ; Y1≈300.3m ; Y5≈297.4m
Fair Price DCF = 8.62 (EV 3.30b - Net Debt -671.6m = Equity 3.97b / Shares 460.4m; r=11.09% [WACC]; 5y FCF grow -4.47% → 2.90% )
EPS Correlation: 37.81 | EPS CAGR: 42.03% | SUE: -4.0 | # QB: 0
Revenue Correlation: 84.15 | Revenue CAGR: 9.78% | SUE: 2.05 | # QB: 3
EPS next Quarter (2026-04-30): EPS=0.15 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=18
EPS next Year (2027-01-31): EPS=0.76 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+13.2% | Growth Revenue=+9.2%